Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial
Objectives: In 2017, the World Health Organisation (WHO) pre-qualified a single-dose typhoid conjugate vaccine (TCV) and identified TCV co-administration studies as a research priority. Accordingly, we tested co-administration of Typbar TCV® (Bharat Biotech International) with measles-rubella (MR) a...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-07-01
|
Series: | International Journal of Infectious Diseases |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971221004616 |
id |
doaj-9644f6197628405ab81ed411d127feb0 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Sodiomon B. Sirima Alphonse Ouedraogo Nouhoun Barry Mohamadou Siribie Alfred Tiono Issa Nébié Amadou Konaté Gloria Damoaliga Berges Amidou Diarra Moussa Ouedraogo Edith C. Bougouma Issiaka Soulama Alimatou Hema Shrimati Datta Yuanyuan Liang Elizabeth T. Rotrosen J. Kathleen Tracy Leslie P. Jamka Jennifer J. Oshinsky Marcela F. Pasetti Kathleen M. Neuzil Matthew B. Laurens |
spellingShingle |
Sodiomon B. Sirima Alphonse Ouedraogo Nouhoun Barry Mohamadou Siribie Alfred Tiono Issa Nébié Amadou Konaté Gloria Damoaliga Berges Amidou Diarra Moussa Ouedraogo Edith C. Bougouma Issiaka Soulama Alimatou Hema Shrimati Datta Yuanyuan Liang Elizabeth T. Rotrosen J. Kathleen Tracy Leslie P. Jamka Jennifer J. Oshinsky Marcela F. Pasetti Kathleen M. Neuzil Matthew B. Laurens Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial International Journal of Infectious Diseases Typhoid conjugate vaccine Typhoid fever Burkina Faso Yellow fever vaccine Coadministration |
author_facet |
Sodiomon B. Sirima Alphonse Ouedraogo Nouhoun Barry Mohamadou Siribie Alfred Tiono Issa Nébié Amadou Konaté Gloria Damoaliga Berges Amidou Diarra Moussa Ouedraogo Edith C. Bougouma Issiaka Soulama Alimatou Hema Shrimati Datta Yuanyuan Liang Elizabeth T. Rotrosen J. Kathleen Tracy Leslie P. Jamka Jennifer J. Oshinsky Marcela F. Pasetti Kathleen M. Neuzil Matthew B. Laurens |
author_sort |
Sodiomon B. Sirima |
title |
Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial |
title_short |
Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial |
title_full |
Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial |
title_fullStr |
Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial |
title_full_unstemmed |
Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial |
title_sort |
safety and immunogenicity of vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in burkina faso: a randomized controlled phase 2 trial |
publisher |
Elsevier |
series |
International Journal of Infectious Diseases |
issn |
1201-9712 |
publishDate |
2021-07-01 |
description |
Objectives: In 2017, the World Health Organisation (WHO) pre-qualified a single-dose typhoid conjugate vaccine (TCV) and identified TCV co-administration studies as a research priority. Accordingly, we tested co-administration of Typbar TCV® (Bharat Biotech International) with measles-rubella (MR) and yellow fever (YF) vaccines. Methods: We conducted a randomized, double-blind, and controlled, phase 2 trial in Ouagadougou, Burkina Faso. Healthy children aged 9–11 months were randomized 1:1 to receive TCV (Group 1) or control vaccine (inactivated polio vaccine (IPV), Group 2). Vaccines were administered intramuscularly with routine MR and YF vaccines. Safety was assessed by (1) local and systemic reactions on days 0, 3, and 7; (2) unsolicited adverse events within 28 days; and (3) serious adverse events (SAEs) within six months after immunization. Results: We enrolled, randomized, and vaccinated 100 eligible children (49 Group 1 and 51 Group 2). Safety outcomes occurred with similar frequency in both groups: local/solicited reactions (Group 1: 1/49, Group 2: 3/50), systemic/solicited reactions (Group 1: 4/49, Group 2: 9/50), unsolicited adverse events (Group 1: 26/49, Group 2: 33/51), and SAEs (Group 1: 2/49, Group 2: 3/51). TCV conferred robust immunogenicity without interference with MR or YF vaccines. Conclusion: TCV can be safely co-administered with MR and YF vaccines to children at the 9-month vaccination visit. |
topic |
Typhoid conjugate vaccine Typhoid fever Burkina Faso Yellow fever vaccine Coadministration |
url |
http://www.sciencedirect.com/science/article/pii/S1201971221004616 |
work_keys_str_mv |
AT sodiomonbsirima safetyandimmunogenicityofvityphoidconjugatevaccinecoadministrationwithroutine9monthvaccinationinburkinafasoarandomizedcontrolledphase2trial AT alphonseouedraogo safetyandimmunogenicityofvityphoidconjugatevaccinecoadministrationwithroutine9monthvaccinationinburkinafasoarandomizedcontrolledphase2trial AT nouhounbarry safetyandimmunogenicityofvityphoidconjugatevaccinecoadministrationwithroutine9monthvaccinationinburkinafasoarandomizedcontrolledphase2trial AT mohamadousiribie safetyandimmunogenicityofvityphoidconjugatevaccinecoadministrationwithroutine9monthvaccinationinburkinafasoarandomizedcontrolledphase2trial AT alfredtiono safetyandimmunogenicityofvityphoidconjugatevaccinecoadministrationwithroutine9monthvaccinationinburkinafasoarandomizedcontrolledphase2trial AT issanebie safetyandimmunogenicityofvityphoidconjugatevaccinecoadministrationwithroutine9monthvaccinationinburkinafasoarandomizedcontrolledphase2trial AT amadoukonate safetyandimmunogenicityofvityphoidconjugatevaccinecoadministrationwithroutine9monthvaccinationinburkinafasoarandomizedcontrolledphase2trial AT gloriadamoaligaberges safetyandimmunogenicityofvityphoidconjugatevaccinecoadministrationwithroutine9monthvaccinationinburkinafasoarandomizedcontrolledphase2trial AT amidoudiarra safetyandimmunogenicityofvityphoidconjugatevaccinecoadministrationwithroutine9monthvaccinationinburkinafasoarandomizedcontrolledphase2trial AT moussaouedraogo safetyandimmunogenicityofvityphoidconjugatevaccinecoadministrationwithroutine9monthvaccinationinburkinafasoarandomizedcontrolledphase2trial AT edithcbougouma safetyandimmunogenicityofvityphoidconjugatevaccinecoadministrationwithroutine9monthvaccinationinburkinafasoarandomizedcontrolledphase2trial AT issiakasoulama safetyandimmunogenicityofvityphoidconjugatevaccinecoadministrationwithroutine9monthvaccinationinburkinafasoarandomizedcontrolledphase2trial AT alimatouhema safetyandimmunogenicityofvityphoidconjugatevaccinecoadministrationwithroutine9monthvaccinationinburkinafasoarandomizedcontrolledphase2trial AT shrimatidatta safetyandimmunogenicityofvityphoidconjugatevaccinecoadministrationwithroutine9monthvaccinationinburkinafasoarandomizedcontrolledphase2trial AT yuanyuanliang safetyandimmunogenicityofvityphoidconjugatevaccinecoadministrationwithroutine9monthvaccinationinburkinafasoarandomizedcontrolledphase2trial AT elizabethtrotrosen safetyandimmunogenicityofvityphoidconjugatevaccinecoadministrationwithroutine9monthvaccinationinburkinafasoarandomizedcontrolledphase2trial AT jkathleentracy safetyandimmunogenicityofvityphoidconjugatevaccinecoadministrationwithroutine9monthvaccinationinburkinafasoarandomizedcontrolledphase2trial AT lesliepjamka safetyandimmunogenicityofvityphoidconjugatevaccinecoadministrationwithroutine9monthvaccinationinburkinafasoarandomizedcontrolledphase2trial AT jenniferjoshinsky safetyandimmunogenicityofvityphoidconjugatevaccinecoadministrationwithroutine9monthvaccinationinburkinafasoarandomizedcontrolledphase2trial AT marcelafpasetti safetyandimmunogenicityofvityphoidconjugatevaccinecoadministrationwithroutine9monthvaccinationinburkinafasoarandomizedcontrolledphase2trial AT kathleenmneuzil safetyandimmunogenicityofvityphoidconjugatevaccinecoadministrationwithroutine9monthvaccinationinburkinafasoarandomizedcontrolledphase2trial AT matthewblaurens safetyandimmunogenicityofvityphoidconjugatevaccinecoadministrationwithroutine9monthvaccinationinburkinafasoarandomizedcontrolledphase2trial |
_version_ |
1721290771806552064 |
spelling |
doaj-9644f6197628405ab81ed411d127feb02021-07-23T04:47:30ZengElsevierInternational Journal of Infectious Diseases1201-97122021-07-01108465472Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trialSodiomon B. Sirima0Alphonse Ouedraogo1Nouhoun Barry2Mohamadou Siribie3Alfred Tiono4Issa Nébié5Amadou Konaté6Gloria Damoaliga Berges7Amidou Diarra8Moussa Ouedraogo9Edith C. Bougouma10Issiaka Soulama11Alimatou Hema12Shrimati Datta13Yuanyuan Liang14Elizabeth T. Rotrosen15J. Kathleen Tracy16Leslie P. Jamka17Jennifer J. Oshinsky18Marcela F. Pasetti19Kathleen M. Neuzil20Matthew B. Laurens21Groupe de Recherche Action en Santé, Ouagadougou, Burkina FasoGroupe de Recherche Action en Santé, Ouagadougou, Burkina FasoGroupe de Recherche Action en Santé, Ouagadougou, Burkina FasoGroupe de Recherche Action en Santé, Ouagadougou, Burkina FasoGroupe de Recherche Action en Santé, Ouagadougou, Burkina FasoGroupe de Recherche Action en Santé, Ouagadougou, Burkina FasoGroupe de Recherche Action en Santé, Ouagadougou, Burkina FasoGroupe de Recherche Action en Santé, Ouagadougou, Burkina FasoGroupe de Recherche Action en Santé, Ouagadougou, Burkina FasoGroupe de Recherche Action en Santé, Ouagadougou, Burkina FasoGroupe de Recherche Action en Santé, Ouagadougou, Burkina FasoGroupe de Recherche Action en Santé, Ouagadougou, Burkina FasoGroupe de Recherche Action en Santé, Ouagadougou, Burkina FasoCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USACenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USACenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USACenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USACenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USACenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USACenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USACenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USACenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA; Corresponding author at: Center for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 W Baltimore St Room 480, Baltimore, MD 21201, USA.Objectives: In 2017, the World Health Organisation (WHO) pre-qualified a single-dose typhoid conjugate vaccine (TCV) and identified TCV co-administration studies as a research priority. Accordingly, we tested co-administration of Typbar TCV® (Bharat Biotech International) with measles-rubella (MR) and yellow fever (YF) vaccines. Methods: We conducted a randomized, double-blind, and controlled, phase 2 trial in Ouagadougou, Burkina Faso. Healthy children aged 9–11 months were randomized 1:1 to receive TCV (Group 1) or control vaccine (inactivated polio vaccine (IPV), Group 2). Vaccines were administered intramuscularly with routine MR and YF vaccines. Safety was assessed by (1) local and systemic reactions on days 0, 3, and 7; (2) unsolicited adverse events within 28 days; and (3) serious adverse events (SAEs) within six months after immunization. Results: We enrolled, randomized, and vaccinated 100 eligible children (49 Group 1 and 51 Group 2). Safety outcomes occurred with similar frequency in both groups: local/solicited reactions (Group 1: 1/49, Group 2: 3/50), systemic/solicited reactions (Group 1: 4/49, Group 2: 9/50), unsolicited adverse events (Group 1: 26/49, Group 2: 33/51), and SAEs (Group 1: 2/49, Group 2: 3/51). TCV conferred robust immunogenicity without interference with MR or YF vaccines. Conclusion: TCV can be safely co-administered with MR and YF vaccines to children at the 9-month vaccination visit.http://www.sciencedirect.com/science/article/pii/S1201971221004616Typhoid conjugate vaccineTyphoid feverBurkina FasoYellow fever vaccineCoadministration |